Trump's Presidency: Impact on the U.S. Biopharma IndustryFDAExplore the implications of Trump's return on U.S. biopharma: healthcare cost reforms, IRA adjustments, reshoring manufacturing, and FDA/NIH shifts. Key focus areas for Chinese pharma include supply chain resilience and navigating new cross-border data regulations.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
